Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

Core Insights - Aptose Biosciences Inc. is advancing its clinical-stage precision oncology drug, tuspetinib, for treating newly diagnosed acute myeloid leukemia (AML) [1][4] - The company has received an additional US$1.5 million from Hanmi Pharmaceutical as part of an US$8.5 million loan facility to support the development of tuspetinib [3] - Shareholders have appointed Ernst & Young LLP as the new independent auditor, which is expected to enhance the company's transparency and growth in the life sciences sector [2] Financial Updates - The total amount received by Aptose under the loan agreement with Hanmi to date is US$7.1 million, indicating significant financial backing for ongoing clinical development [3] - The additional advance of US$1.5 million is part of a structured financial strategy to ensure continued progress in drug development [3] Corporate Governance - The appointment of Ernst & Young LLP as the independent auditor reflects the company's commitment to maintaining high standards of financial oversight and transparency [2] - The decision was made during a reconvened annual and special meeting of shareholders, highlighting active shareholder engagement in corporate governance [1][2]